학술논문
EE437 Healthcare Resource Utilization and Costs in Patients with Multiple Myeloma Who Received 1 to 3 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and Exposed to (AND DISCONTINUED) Lenalidomide in the United States
Document Type
Abstract
Author
Source
In Value in Health July 2022 25(7) Supplement:S420-S420
Subject
Language
ISSN
1098-3015